Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

On the heels of a fall and winter that saw hundreds of Alberta babies and toddlers hospitalized and two young children die ...

RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...